New estimates of the costs of adverse events in patients with cancer.

ABSTRACT: The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leuke

SUBMITTER: Patel A 

PROVIDER: S-EPMC12478943 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature